Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

Novartis International AG / Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

• Driving growth through cutting edge pipeline with 15 in-market blockbusters and more than 25 potential blockbusters in development, including 10+ planned launches by 2021
   

Strong progress on productivity efforts to expand margins with acceleration of key growth drivers, together with productivity efforts in Novartis Technical Operations and Business Services
 

Building leadership in advanced therapy platforms with 18 projects in clinical development
 

Continuing a multi-year journey to build a new culture and create lasting trust and impact with society

Basel, May 23, 2019 - Novartis hosts its annual Meet Novartis Management event today at its Research headquarters in Cambridge, Massachusetts, giving investors and industry analysts the opportunity to meet with key executives across the company in six separate breakout sessions. The meeting provides a deeper view into the company's progress on its ongoing transformation and strategy for sustainable value creation.

"Novartis is on track to become a leading medicines company powered by advanced therapy platforms and data science, and is on track to deliver sustained accretive growth. We are developing and launching medicines that can change the standard of care in devastating diseases. Our pipeline is industry-leading with more than 25 potential blockbusters and this pace of innovation positions Novartis well for the future", said Novartis CEO, Vas Narasimhan.   

In the Pharmaceuticals business unit, management highlights the continued strength of Cosentyx and Entresto and preparation for an unprecedented wave of launches. Strong momentum continues for key growth drivers based on a growing evidence base, including the PIONEER data supporting hospital initiation of Entresto. The team is ready to launch five blockbuster candidates in core therapeutic areas over the next two years - Mayzent, Zolgensma[1], Brolucizumab (RTH258), Ofatumumab (OMB157), and Fevipiprant (QAW039). Novartis also expects double-digit growth in China, capitalizing on faster and broader access.